Professor Peter Schmid Frcp Md Phd

MedSIR's PHERGain clinical trial by Prof. Peter Schmid

Treatment Options for Triple-Negative Breast Cancer Prof. Peter Schmid

Oncology Events

Prof. Peter Schmid talking about how MedSIR run international clinical trials

Come listen Prof. Peter Schmid talking about clinical trials

Challenges in the treatment of mTNBC

Catching up with Peter Schmid, MD, lead investigator for KEYNOTE-522

Living Beyond Breast Cancer

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal

PeerView Oncology

eCME on "How shall we Treat Triple-Negative Breast Cancer (TNBC)"

Oncology Club Bangladesh

The future therapeutic landscape of immunotherapy for mTNBC

The addition of platinum compounds to standard chemotherapy for breast cancer patients

Biosimilars for breast cancer treatment

EMJ

Final results of PAKT: capivasertib and paclitaxel for TNBC

Current gold standard for TNBC and Future direction | Peter Schmid

Oncology Club Bangladesh

Dr. Schmid on Evaluating Biosimilars in Oncology

IMpassion130 study: improvement in OS and PFS for IIT and PD-L1+ populations with mTNBC

Prof. Peter Schmid | Presentation | 2nd Breast Cancer Preceptorship Program | BSBCS

Bangladesh Society for Breast Cancer Study

ClarifyingComplexities of ExpandingTreatmentOptionsFor AdvancedAndEarly-Stage HR+/HER2- BreastCancer

PeerView Oncology

Highlights from SABCS 2021: T-DXd, KEYNOTE-355, PADA-1 & EMERALD

TNBC: work to be done

LDR-brachytherapy for PCa Hans-Peter Schmid, St. Gallen